Achieve Life Sciences, Inc.

As of June 30, 2026, Achieve Life Sciences, Inc. carries a market capitalization of 588.96M, placing it among publicly traded companies globally. Its enterprise value stands at 438.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Achieve Life Sciences, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Achieve Life Sciences, Inc. has 102.66M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Achieve Life Sciences, Inc. maintains a current ratio of 0.95, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -101.85, indicating conservative leverage, while an interest coverage ratio of -58.44 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -91.46, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 27.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Achieve Life Sciences, Inc.'s stock has gained approximately 34.16% over the past 52 weeks. The 50-day moving average sits at 6.64, while the 200-day moving average is 4.89.

Over the twelve months ended June 30, 2026, Achieve Life Sciences, Inc. generated - - in revenue and converted that into -99.82M in net income, yielding earnings per share of -1.59. EBITDA reached -50.84M, while operating income came in at -51.01M.

As of June 30, 2026, Achieve Life Sciences, Inc. holds 163.95M in cash and equivalents against 13.08M in total debt, resulting in a net debt position of -28.93M. Total book value stands at -12.85M, with working capital of -8.20M providing operational flexibility.

Achieve Life Sciences, Inc. produced -41.15M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.42: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -26.57, meaning Achieve Life Sciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Achieve Life Sciences, Inc.'s most recent stock split took place on July 31, 2020 with a 20:1 split ratio.

As of June 30, 2026, Achieve Life Sciences, Inc. has an Altman Z-Score of -1.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.